What is Radiomics?
Turning medical images into data
What’s going on at radiomics.bio?
The latest News
Posted October 16th, 2025
News
radiomics.bio and AstraZeneca join forces to explore the potential for an AI model to predict interstitial lung disease related to cancer treatment
Posted January 10th, 2025
Press Release
radiomics.bio Announces New Chairman
Posted February 29th, 2024
News
From Images to Impact: Radiomics’ Solutions to Challenges in Immunotherapy
Posted September 5th, 2023
News
Pilot project at the Jewish General Hospital aims to accelerate access to new and highly effective treatments for cancer patients
Posted April 7th, 2023
News
Belgian biotech companies DeuterOncology and Radiomics combine their expertise to improve cancer therapy
Posted November 23rd, 2022
News
Radiomics’ Event Package For IO Xchange
Publications
The latest Papers
Predictive value of baseline and longitudinal MRI radiomics for intracranial progression-free survival in ALK-positive NSCLC patients with brain metastases
Predicting intracranial progression-free survival (iPFS) is crucial for managing ALK-positive NSCLC patients with brain metastases…
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
Immunotherapy of cancer is now an essential pillar of treatment for patients with…
Exploratory radiomics analysis in unresectable hepatocellular carcinoma treated with durvalumab alone or combined with tremelimumab or bevacizumab
We analyzed baseline and end-of-treatment (EOT) abdominal CT scans to explore associations between image features and clinical outcomes…
Baseline and early follow-up radiomics biomarkers for tumor growth in uveal melanoma patients treated with roginolisib (IOA-244)
This study investigated lesion-level radiomic features from baseline and early follow-up scans to identify individual tumor growth profiles…
Quantitative radiomics for the detection of symptomatic pneumonitis following chemoradiotherapy in patients with stage III unresectable NSCLC
A proprietary radiomic assessment with an auto segmentation model was applied to CT images to identify 4 abnormality patterns…
Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ)…
Radiomic assessment in UM patients detects mixed responses in…